TYMS and lung carcinoma: The expression levels of pyrimidine metabolic rate–limiting enzymes CAD, CTPS, DTYMK, RRM1, RRM2, TYMS, UCK2, and TK1 were particularly higher in TP53 mutant lung cancer patients (Fig. 8c).